A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630 | Zendy

Yuri Taniguchi | Zendy; Tsuneo Shimokawa | Zendy; Yuichi Takiguchi | Zendy; Toshihiro Misumi | Zendy; Yukiko Nakamura | Zendy; Yosuke Kawashima | Zendy; Naoki Furuya | Zendy; Yoshimasa Shiraishi | Zendy; Toshiyuki Harada | Zendy; Hisashi Tanaka | Zendy; Satoru Miura | Zendy; Ayumi Uchiyama | Zendy; Yoshiro Nakahara | Zendy; Takaaki Tokito | Zendy; Katsuhiko Naoki | Zendy; Akihiro Bessho | Zendy; Yasuhiro Gotô | Zendy; Masahiro Seike | Zendy; Hiroaki Okamoto | Zendy

Open Access

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630

Author(s) -

Yuri Taniguchi,

Tsuneo Shimokawa,

Yuichi Takiguchi,

Toshihiro Misumi,

Yukiko Nakamura,

Yosuke Kawashima,

Naoki Furuya,

Yoshimasa Shiraishi,

Toshiyuki Harada,

Hisashi Tanaka,

Satoru Miura,

Ayumi Uchiyama,

Yoshiro Nakahara,

Takaaki Tokito,

Katsuhiko Naoki,

Akihiro Bessho,

Yasuhiro Gotô,

Masahiro Seike,

Hiroaki Okamoto

Publication year - 2022

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-22-1687

Subject(s) - nivolumab , medicine , docetaxel , clinical endpoint , lung cancer , chemotherapy , phases of clinical research , adverse effect , oncology , surgery , cancer , progression free survival , combination therapy , gastroenterology , randomized controlled trial , urology , immunotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research